Lantern Pharma Inc. Common Stock (LTRN)
Stock · NASDAQ · Health Care
$0.6531as of 10/16/2026
Price chart
Active signals
LTRN Signal Track Record
How signals performed across all stocks →What LTRN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 47 | -1.3% | 47% | September 16, 2026 |
| Bollinger Band Breakdown | 25 | +2.7% | 56% | September 22, 2026 |
| Bollinger Band Breakout | 18 | -3.0% | 44% | May 14, 2026 |
| 200-Day Moving Average TouchActive now | 18 | -4.2% | 28% | May 21, 2026 |
| Any 20-session window (baseline) | -3.2% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LTRN
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic,…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 16
- Website
- www.lanternpharma.com/
Fundamentals
- 1-day range
- $0.6551$0.7055
- Market cap
- $35.47M
- P/E (trailing)
- —
- P/E (forward)
- -0.33
- EPS (trailing)
- $-1.61
- Dividend yield
- —
- Beta
- 2.42
- Avg. volume
- 183.3K
Forecasts
2 analyst ratings
Lantern Pharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LTRNLantern Pharma Inc. Common Stock$0.668▲ 0.15%Market cap $35.47MP/E —$0.651$4.58
- NNVCNanoViricides Inc. Common Stock$1.38▲ 0.73%Market cap $35.56MP/E —$0.85$2.23
- SERSerina Therapeutics Inc. Common Stock$1.72▼ 3.91%Market cap $35.24MP/E —$1.22$5.29
- BYSIBeyondSpring Inc. Ordinary Shares$0.559▼ 3.95%Market cap $35.77MP/E —$0.5657$2.44
- VERUVeru Inc. Common Stock$2.3▼ 5.74%Market cap $37.08MP/E —$2.05$7.33
- IXHLIncannex Healthcare Inc. Common Stock$2.82▼ 2.08%Market cap $37.21MP/E —$2.49$14.91
- CRVOCervoMed Inc. Common Stock$2.24▼ 0.44%Market cap $37.33MP/E —$2.13$10
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LTRN Lantern Pharma Inc. Common Stock | $35.47M | — | $0.668 | ▲ 0.15% | $0.651$4.58 |
| NNVC NanoViricides Inc. Common Stock | $35.56M | — | $1.38 | ▲ 0.73% | $0.85$2.23 |
| SER Serina Therapeutics Inc. Common Stock | $35.24M | — | $1.72 | ▼ 3.91% | $1.22$5.29 |
| BYSI BeyondSpring Inc. Ordinary Shares | $35.77M | — | $0.559 | ▼ 3.95% | $0.5657$2.44 |
| VERU Veru Inc. Common Stock | $37.08M | — | $2.3 | ▼ 5.74% | $2.05$7.33 |
| IXHL Incannex Healthcare Inc. Common Stock | $37.21M | — | $2.82 | ▼ 2.08% | $2.49$14.91 |
| CRVO CervoMed Inc. Common Stock | $37.33M | — | $2.24 | ▼ 0.44% | $2.13$10 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- What Could Go Wrong With Recursion Pharmaceuticals Stock?Yahoo · 10/8/2026
- Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026Yahoo · 10/8/2026
- Lantern Pharma secures Taiwan clearances for Phase II NSCLC studyYahoo · 10/8/2026
- Lantern Pharma Announces Taiwan Approvals To Open Next Stage Of Phase 2 LP-300 Trial In Never-Smoker Lung Cancerbenzinga · 10/7/2026
- Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLCYahoo · 10/7/2026
- Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct OfferingYahoo · 9/30/2026
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga · 9/29/2026
- Lantern Pharma Inc. Announces up to $8 Million Registered Direct OfferingYahoo · 9/29/2026
- New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace GlobalYahoo · 9/26/2026
Insider Activity
Insider Actions →- Lee Troy Schalop · May 12, 2026 · Buy48.5K @ $2.06
- D. Jeffrey Keyser · May 12, 2026 · Buy48.5K @ $2.06
Institutional Ownership
March 31, 2026
- Total shares held
- 2.02M
- Total value held
- $2.76M
- Institutional holders
- 29
- Unknown864.4K
- Unknown332.1K
- Unknown250.0K
- Unknown116.0K
- Unknown111.6K
- Unknown50.0K
- Unknown50.0K
- Unknown45.3K
- Unknown38.1K
- Unknown26.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Lantern Pharma Announces $8M Direct Offering and AI Roadmap
Lantern Pharma said it will raise up to $8 million through a registered direct offering. The company also outlined its Open‑Medicine AI platform roadmap, highlighting plans to use agentic AI for drug development. It presented these ideas on Bloomberg Television and in a SeekingAlpha slideshow. The move could support future product pipelines, while the stock’s low RSI and recent volume spike suggest increased investor interest.
Lantern Pharma Announces $8M Direct Offering and AI Roadmap. Lantern Pharma said it will raise up to $8 million through a registered direct offering. The company also outlined its Open‑Medicine AI platform roadmap, highlighting plans to use agentic AI for drug development. It presented these ideas on Bloomberg Television and in a SeekingAlpha slideshow. The move could support future product pipelines, while the stock’s low RSI and recent volume spike suggest increased investor interest.